Study details
Enrolling now
Neutralizing Interleukin (IL)-6
Icahn School of Medicine at Mount Sinai
NCT IDNCT07493317ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18–70
Locations
1 site in NY
What this study is about
This Phase 2 study is testing Tocilizumab in people with depression.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
tocilizumab (Monoclonal antibody; blocks IL-6 receptor to reduce inflammation)
Drug routes
infusion
Endpoints
Secondary: Change in Montgomery-Asberg Depression Rating Scale (MADRS)
Body systems
Psychiatry / Mental Health